Stocks Health care MPLT
NASDAQ · Health careMapLight Therapeutics, Inc. (MPLT)
It posted a net loss of $229.8M. In fiscal 2025 capital spending exceeded operating cash flow by $138.6M. At June 30, 2026 it held $71.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What MapLight Therapeutics, Inc. does
MapLight Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MPLT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$161.2M | -$18.56 | -$138.6M |
| 2025 | n/a | -$77.6M | -$105.38 | -$79.6M |
Latest SEC filings
What MapLight Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026
- September 18, 2026
- September 9, 2026IPO registration S-1
- August 20, 2026Passive stake (5% or more) SCHEDULE 13G
- August 18, 2026Activist stake changed SCHEDULE 13D/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- August 3, 2026Activist stake changed SCHEDULE 13D/A
- July 31, 2026Activist stake changed SCHEDULE 13D/A
- July 27, 2026
Questions about MPLT
What does MapLight Therapeutics, Inc. do?
MapLight Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MPLT.
Is MapLight Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $229.8M.
When did MapLight Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the securities offering prospectus from September 23, 2026.
Similar companies
Follow MPLT
Get an email when MapLight Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow MPLT: get an email when it filesWhere the numbers come from
Financial figures are the values MapLight Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.